RxDoctor Payments Data

Edgar Musngi, MD

Nephrology · Torrance, CANPI 1871523563

Payments from drug & device makers

$4,505in general payments, 2019–2025

Across 229 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$533
  • Travere Therapeutics, Inc.$510
  • AstraZeneca$494
  • Amgen$433
  • Otsuka America Pharmaceutical, Inc.$305
  • OPKO Pharmaceuticals, LLC$288
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,39998%
  • Education$1062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,505 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$707,041
Medicare patients
633
Services billed
4,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin254$270,220
FarxigaDapagliflozin Propanediol203$235,014
JynarqueTolvaptan12$232,053
LokelmaSodium Zirconium Cyclosilicate71$63,142
VelphoroSucroferric Oxyhydroxide11$48,499
ProcritEpoetin Alfa56$48,367
RybelsusSemaglutide35$43,215
XphozahTenapanor Hcl14$41,037
Sevelamer Carbonate162$39,790
VeltassaPatiromer Calcium Sorbitex36$39,700
RenvelaSevelamer Carbonate20$31,104
KerendiaFinerenone16$17,164
JanuviaSitagliptin Phosphate15$17,030
AuryxiaFerric Citrate12$15,127
OzempicSemaglutide14$14,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$494$298,156274 claims
Boehringer IngelheimJardiance$70$270,220254 claims
Otsuka America Pharmaceutical, Inc.Jynarque$305$232,05312 claims
Novo NordiskRybelsus, Ozempic$255$57,76749 claims
Fresenius USA Marketing, Inc.Velphoro$74$48,49911 claims
Johnson & JohnsonProcrit$236$48,36756 claims
BayerKerendia$74$17,16416 claims
Akebia Therapeutics IncAuryxia$265$15,12712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.

Other nephrology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →